{"id":"NCT00958568","sponsor":"Eli Lilly and Company","briefTitle":"A Study in Relapse Prevention of Treatment-Resistant Depression","officialTitle":"A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Only in the Relapse Prevention of Stabilized Patients With Treatment-Resistant Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2012-03","completion":"2012-03","firstPosted":"2009-08-13","resultsPosted":"2014-04-01","lastUpdate":"2014-04-01"},"enrollment":892,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Treatment Resistant Depression"],"interventions":[{"type":"DRUG","name":"Olanzapine and Fluoxetine combination (OFC)","otherNames":["Symbyax","LY900000"]},{"type":"DRUG","name":"Fluoxetine","otherNames":["Prozac","LY1101440"]}],"arms":[{"label":"Olanzapine and Fluoxetine combination (OFC)","type":"EXPERIMENTAL"},{"label":"Fluoxetine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine whether olanzapine and fluoxetine combination (OFC) if used for a long time (47 weeks) makes patients suffering from Treatment Resistant Depression stable, determine if OFC is safe when used to treat patients with Treatment Resistant Depression for a long time (up to 47 weeks), to determine whether olanzapine and fluoxetine combination or fluoxetine alone is better to treat Treatment Resistant Depression when treated for a long time (up to 47 weeks) and to assess the quality of life during treatment.","primaryOutcome":{"measure":"Time to Relapse by Any Criteria","timeFrame":"Randomization (Week 20) to Week 47","effectByArm":[{"arm":"OFC (SPIV)","deltaMin":null,"sd":10},{"arm":"Flu (SPIV)","deltaMin":null,"sd":5.9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":66,"countries":["United States","Argentina","India","Mexico","Puerto Rico","Russia","South Africa","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":892},"commonTop":["Weight increased","Increased appetite","Dry mouth","Headache","Somnolence"]}}